Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2014

View Archived Issues

Gut-targeted anti-TNF polyclonal antibody granted U.S orphan status for pediatric ulcerative colitis

Milestone Pharmaceuticals reports phase I data for MSP-2017

In vivo data show strong antitumor activity of the novel FGFR/VEGR inhibitor ODM-203

Endo acquires rights to Natesto testosterone nasal gel

OncoSec and UCSF collaborate to study pembrolizumab and ImmunoPulse in metastatic melanoma

Orgenesis receives grant for autologous hepatocyte-derived therapy for type 1 diabetes

Low-affinity NMDA channel blockers could be useful for Rett syndrome

Adiponectin-like peptide agonist useful for hepatic fibrosis

Amarantus reports preclinical data on MANF in a model of retinitis pigmentosa

Antiviral drug discovery companies Cocrystal Pharma and RFS Pharma complete merger

Phase I results demonstrate safety of CTO plus bevacizumab in patients with malignant glioma

Researchers present in vivo data for a novel highly selective aldosterone synthase inhibitor

Antibe Therapeutics discloses HS-releasing prostaglandin inhibitor for acute pain

Interferon gene signature suppression with sifalimumab and anifrolumab in patients with SLE

Nordic Nanovector and Affibody collaborate on radioimmunotherapies for multiple myeloma

FDA requests additional data on daclatasvir in combination with other HCV drugs

Vargatef approved in E.U. for second-line treatment of NSCLC

Brd4 inhibitors prepared and tested at Gilead Sciences

Janssen patent describes compounds for HBV infection

Boehringer Ingelheim reports development of ACC2 inhibitors

Merck & Co. divulges HIV integrase inhibitors

FDA issues complete response letter for Avanir's AVP-825 for migraine

Spanish researchers describe HDAC inhibitors

Intra-Cellular Therapies initiates phase III trial of ITI-007 in schizophrenia

Regen BioPharma acquires cancer stem cell intellectual property from University of Toronto

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...